Accessibility Menu
4DMedical logo

4DMedical(ASX) 4DX

Market CapA$2.30BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)+141%
5 Year+169%
1 Year+590%
1 Month+13%
A$3.83
-4.73%
-0.19Today
4DMedical last closing stock price
MetricPriceDate
Last closeAUD 3.832026-08-21
4DMedical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+5.22%AUD 3.642026-08-14
1 month+12.98%AUD 3.392026-07-22
3 month+5.8%AUD 3.622026-05-22
Year to date-2.54%AUD 3.932025-12-31
1 year+590.09%AUD 0.562025-08-21
3 year+512.8%AUD 0.632023-08-22
5 year+168.77%AUD 1.432021-08-20
Since inception+140.88%AUD 1.592020-08-07

4DMedical Financials at a Glance

Market Cap

A$2.30BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$10.19M

Net Income (TTM)

-A$199.13M

EPS (TTM)

-A$0.34

P/E Ratio

-11.42

Dividend

A$0.00

Beta (Volatility)

-0.14 (Low)

Price

A$3.83

Volume

3,079,212

Open

A$3.98

Previous Close

A$3.83

Daily Range

A$3.81 - A$3.98

52-Week Range

A$0.47 - A$7.55

Estimated Earnings Date

Aug 27, 2026

4DX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About 4DMedical

4DMedical Limited is a medical technology company based in Carlton, Australia, specializing in advanced lung imaging solutions. The firm focuses on its proprietary XV Technology, which offers four-dimensional lung imaging, enhancing diagnostic capabilities in respiratory health.

Products and Services
  • Innovative XV Technology for four-dimensional lung imaging
  • Software-as-a-service (SaaS) delivery model for lung ventilation analysis
  • Permetium, a preclinical imaging system for pulmonary function assessment
Growth Outlook
  • Significant market potential in the medical imaging sector
  • Expansion plans into the United States to increase market reach
  • Continuous innovation in lung health technology to drive future growth
Financial Highlights
  • Recent quarterly revenue of AUD 2.85 million, showing growth potential
  • Cash and cash equivalents of AUD 56.76 million, providing operational stability
  • Current ratio of 6.57, indicating strong liquidity position
4DMedical Limited operates in a promising sector with a focus on innovative technology that addresses critical healthcare needs. The company's XV Technology is positioned to transform lung imaging, offering significant advantages over traditional methods. With a robust cash position and a strong current ratio, the company is well-equipped to navigate its growth strategy and capitalize on market opportunities. The expansion into the U.S. market and ongoing product development are expected to enhance its competitive edge, making it an intriguing prospect for investors interested in the healthcare technology space.
AI Generated • Aug 21, 2026

Industry

Health Care Technology

Sector

Health Care

Employees

124

CEO

Andreas Fouras, PhD

Website

www.4dmedical.com

Headquarters

Carlton, VIC 3053, AU

4DX Financials

Key Financial Metrics (TTM)

Gross Margin

-396.61%

Operating Margin

-1166.28%

Net Income Margin

-3684.62%

Return on Equity

-890.76%

Return on Capital

-69.30%

Return on Assets

-114.36%

Earnings Yield

-8.76%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$2.30BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

599.93M

Volume

3.08M

Avg. Volume

6.12M

Financials (TTM)

Gross Profit

-A$11.70M

Operating Income

-A$77.97M

EBITDA

-A$80.10M

Operating Cash Flow

-A$53.10M

Capital Expenditure

-A$258.42K

Free Cash Flow

-A$53.36M

Cash & ST Invst.

A$56.76M

Total Debt

A$6.42M

4DMedical Performance Analysis

4DMedical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 1,054,300N/A
20232023-06-30AUD 718,581-31.8%
20242024-06-30AUD 3,754,256422.5%
20252025-06-30AUD 5,853,40155.9%
4DMedical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30273.7%
Q22024-12-31-2.2%
Q42025-06-30-48.9%
Q22025-12-3192.8%
4DMedical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD -0.08N/A
20232023-06-30AUD -0.1025.6%
20242024-06-30AUD -0.10-7.4%
20252025-06-30AUD -0.07-27.0%
4DMedical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30-18.1%
Q22024-12-3137.5%
Q42025-06-3057.1%
Q22025-12-31-2230.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$2.85M

+259.9%

Gross Profit

-A$18.52M

-44.5%

Gross Margin

-6.49%

N/A

Market Cap

A$2.30BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$18.53M

N/A

Employees

124

N/A

Net Income

-A$154.14M

-887.7%

EBITDA

-A$23.78M

-42.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$56.76M

+18.6%

Total Debt

A$6.42M

-66.6%

Accounts Receivable

A$3.11M

-69.9%

Inventory

A$919.63K

-17.3%

Long Term Debt

A$5.27M

-71.6%

Short Term Debt

A$1.14M

-11.6%

Return on Assets

-1.14%

N/A

Return on Invested Capital

-38.89%

N/A

Free Cash Flow

-A$12.80M

+16.7%

Operating Cash Flow

-A$12.66M

+14.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AVR.AXAnteris Technologies Ltd
A$12.63-6.44%
PYC.AXPYC Therapeutics Limited
A$2.07-5.91%
IDX.AXIntegral Diagnostics Limited
A$2.25-1.32%
PNV.AXPolyNovo Limited
A$1.07-3.60%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.77+0.10%
IBITiShares Bitcoin Trust
$43.68+0.06%
BITOProShares Trust - ProShares Bitcoin ETF
$10.41+0.06%
MARAMara Holdings
$11.26+0.01%

Questions About 4DX

What is the current price of 4DMedical?

4DMedical is trading at A$3.83 per share.

What is the 52-week range for 4DMedical?

Over the past 52 weeks, 4DMedical has traded between A$0.47 and A$7.55.

How much debt does 4DMedical have?

As of the most recent reporting period, 4DMedical reported total debt of A$4.31M.

How much cash does 4DMedical have on hand?

4DMedical reported A$6.88M in cash and cash equivalents in its most recent financial results.

What is 4DMedical’s dividend yield?

4DMedical does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services